{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T09:11:05Z","timestamp":1782551465017,"version":"3.54.5"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,3,25]],"date-time":"2024-03-25T00:00:00Z","timestamp":1711324800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,3,25]],"date-time":"2024-03-25T00:00:00Z","timestamp":1711324800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Exp Clin Cancer Res"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Pancreatic cancer (PC) is a highly malignant gastrointestinal tumor, which is characterized by difficulties in early diagnosis, early metastasis, limited therapeutic response and a grim prognosis. Therefore, it is imperative to explore potential therapeutic targets for PC. Currently, although the involvement of the Pellino E3 Ubiquitin Protein Ligase 1 (PELI1) in the human growth of some malignant tumors has been demonstrated, its association with PC remains uncertain.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Bioinformatics, qRT-PCR, Western blot and IHC were used to detect the expression of PELI1 in pancreas or PC tissues and cells at mRNA and protein levels. The effects of PELI1 on the proliferation and metastatic ability of pancreatic cancer in vitro and in vivo were investigated using CCK8, cloning\u00a0formation, EdU, flow cytometry, IHC, Transwell assay, wound healing, nude mice subcutaneous tumorigenesis and intrasplenic injection to construct a liver metastasis model. The interactions of PELI1 with proteins as well as the main functions and pathways were investigated by protein profiling, Co-IP, GST-pull down, Immunofluorescence techniques,\u00a0immunohistochemical co-localization and enrichment analysis. The rescue experiment verified the above experimental results.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The mRNA and protein expression levels of PELI1 in PC tissues were upregulated and were associated with poor prognosis of patients, in vitro and in vivo experiments confirmed that PELI1 can affect the proliferation and metastatic ability of PC cells. Co-IP, GST-pull down, and other experiments found that PELI1 interacted with Ribosomal Protein S3 (RPS3) through the FHA structural domain and promoted the polyubiquitination of RPS3 in the K48 chain, thereby activates the PI3K\/Akt\/GSK3\u03b2 signaling pathway. Moreover, ubiquitinated degradation of RPS3 further reduces Tumor Protein P53 (p53) protein stability and increases p53 degradation by MDM2 Proto-Oncogene (MDM2).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>PELI1 is overexpressed in PC, which increased ubiquitination of RPS3 proteins and activates the PI3K\/Akt\/GSK3\u03b2 signaling pathway, as well as reduces the protective effect of RPS3 on p53 and promotes the degradation of the p53 protein, which facilitates the progression of PC and leads to a poor prognosis for patients. Therefore, PELI1 is a potential target for the treatment of PC.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13046-024-03008-9","type":"journal-article","created":{"date-parts":[[2024,3,25]],"date-time":"2024-03-25T08:01:51Z","timestamp":1711353711000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["PELI1: key players in the oncogenic characteristics of pancreatic Cancer"],"prefix":"10.1186","volume":"43","author":[{"given":"Xiaobin","family":"Fei","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changhao","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Songbai","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Likun","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rishang","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junyi","family":"Hou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongjia","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9300-382X","authenticated-orcid":false,"given":"Yaozhen","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,3,25]]},"reference":[{"issue":"1","key":"3008_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21708","volume":"72","author":"RL Siegel","year":"2022","unstructured":"Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA Cancer J Clin. 2022;72(1):7\u201333. https:\/\/doi.org\/10.3322\/caac.21708.","journal-title":"CA Cancer J Clin."},{"issue":"3","key":"3008_CR2","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209\u201349. https:\/\/doi.org\/10.3322\/caac.21660.","journal-title":"CA Cancer J Clin."},{"issue":"2","key":"3008_CR3","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1053\/j.gastro.2022.03.056","volume":"163","author":"LD Wood","year":"2022","unstructured":"Wood LD, Canto MI, Jaffee EM, Simeone DM. Pancreatic Cancer: pathogenesis, screening, diagnosis, and treatment. Gastroenterol. 2022;163(2):386\u2013402.e1. https:\/\/doi.org\/10.1053\/j.gastro.2022.03.056.","journal-title":"Gastroenterol."},{"issue":"8","key":"3008_CR4","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.1016\/j.cell.2023.02.014","volume":"186","author":"CJ Halbrook","year":"2023","unstructured":"Halbrook CJ, Lyssiotis CA. Pasca di Magliano M, Maitra A. Pancreatic cancer: Adv chall Cell. 2023;186(8):1729\u201354. https:\/\/doi.org\/10.1016\/j.cell.2023.02.014.","journal-title":"Pancreatic cancer: Adv chall Cell."},{"key":"3008_CR5","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1016\/j.semcancer.2021.05.030","volume":"76","author":"B Traub","year":"2021","unstructured":"Traub B, Link KH, Kornmann M. Curing pancreatic cancer. Semin Cancer Biol. 2021;76:232\u201346. https:\/\/doi.org\/10.1016\/j.semcancer.2021.05.030.","journal-title":"Semin Cancer Biol."},{"key":"3008_CR6","doi-asserted-by":"publisher","first-page":"102180","DOI":"10.1016\/j.ctrv.2021.102180","volume":"96","author":"S De Dosso","year":"2021","unstructured":"De Dosso S, Siebenh\u00fcner AR, Winder T, Meisel A, Fritsch R, Astaras C, et al. Treatment landscape of metastatic pancreatic cancer. Cancer Treat Rev. 2021;96:102180. https:\/\/doi.org\/10.1016\/j.ctrv.2021.102180.","journal-title":"Cancer Treat Rev."},{"issue":"1","key":"3008_CR7","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1186\/s12943-018-0858-1","volume":"17","author":"B Ren","year":"2018","unstructured":"Ren B, Cui M, Yang G, Wang H, Feng M, You L, et al. Tumor microenvironment participates in metastasis of pancreatic cancer. Mol Cancer. 2018;17(1):108. https:\/\/doi.org\/10.1186\/s12943-018-0858-1.","journal-title":"Mol Cancer."},{"issue":"7","key":"3008_CR8","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1038\/s41575-021-00457-x","volume":"18","author":"AP Klein","year":"2021","unstructured":"Klein AP. Pancreatic cancer epidemiology: understanding the role of lifestyle and inherited risk factors. Nat Rev Gastroenterol Hepatol. 2021;18(7):493\u2013502. https:\/\/doi.org\/10.1038\/s41575-021-00457-x.","journal-title":"Nat Rev Gastroenterol Hepatol."},{"issue":"6","key":"3008_CR9","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1158\/2159-8290.CD-20-0359","volume":"10","author":"F Bednar","year":"2020","unstructured":"Bednar F, Pasca di Magliano M. Chemotherapy and tumor evolution shape pancreatic Cancer recurrence after resection. Cancer Discov. 2020;10(6):762\u20134. https:\/\/doi.org\/10.1158\/2159-8290.CD-20-0359.","journal-title":"Cancer Discov."},{"issue":"5","key":"3008_CR10","doi-asserted-by":"publisher","first-page":"1920","DOI":"10.1002\/med.21675","volume":"40","author":"MD Asmamaw","year":"2020","unstructured":"Asmamaw MD, Liu Y, Zheng YC, Shi XJ, Liu HM. Skp2 in the ubiquitin-proteasome system: a comprehensive review. Med Res Rev. 2020;40(5):1920\u201349. https:\/\/doi.org\/10.1002\/med.21675.","journal-title":"Med Res Rev."},{"issue":"11","key":"3008_CR11","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1016\/j.tibs.2022.06.006","volume":"47","author":"V Osei-Amponsa","year":"2022","unstructured":"Osei-Amponsa V, Walters KJ. Proteasome substrate receptors and their therapeutic potential. Trends Biochem Sci. 2022;47(11):950\u201364. https:\/\/doi.org\/10.1016\/j.tibs.2022.06.006.","journal-title":"Trends Biochem Sci."},{"key":"3008_CR12","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1146\/annurev-biochem-051810-094654","volume":"81","author":"K Husnjak","year":"2012","unstructured":"Husnjak K, Dikic I. Ubiquitin-binding proteins: decoders of ubiquitin-mediated cellular functions. Annu Rev Biochem. 2012;81:291\u2013322. https:\/\/doi.org\/10.1146\/annurev-biochem-051810-094654.","journal-title":"Annu Rev Biochem."},{"issue":"8","key":"3008_CR13","doi-asserted-by":"publisher","first-page":"1424","DOI":"10.1016\/j.molcel.2022.02.004","volume":"82","author":"D Sherpa","year":"2022","unstructured":"Sherpa D, Chrustowicz J, Schulman BA. How the ends signal the end: regulation by E3 ubiquitin ligases recognizing protein termini. Mol Cell. 2022;82(8):1424\u201338. https:\/\/doi.org\/10.1016\/j.molcel.2022.02.004.","journal-title":"Mol Cell."},{"key":"3008_CR14","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1146\/annurev-biochem-032620-104421","volume":"91","author":"AD Cowan","year":"2022","unstructured":"Cowan AD, Ciulli A. Driving E3 ligase substrate specificity for targeted protein degradation: lessons from nature and the laboratory. Annu Rev Biochem. 2022;91:295\u2013319. https:\/\/doi.org\/10.1146\/annurev-biochem-032620-104421.","journal-title":"Annu Rev Biochem."},{"issue":"3","key":"3008_CR15","doi-asserted-by":"publisher","first-page":"e1204","DOI":"10.1002\/ctm2.1204","volume":"13","author":"C Sampson","year":"2023","unstructured":"Sampson C, Wang Q, Otkur W, Zhao H, Lu Y, Liu X, et al. The roles of E3 ubiquitin ligases in cancer progression and targeted therapy. Clin translat med. 2023;13(3):e1204. https:\/\/doi.org\/10.1002\/ctm2.1204.","journal-title":"Clin translat med."},{"issue":"Pt B","key":"3008_CR16","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.arr.2015.07.009","volume":"24","author":"A Upadhyay","year":"2015","unstructured":"Upadhyay A, Amanullah A, Chhangani D, Mishra R, Mishra A. Selective multifaceted E3 ubiquitin ligases barricade extreme defense: potential therapeutic targets for neurodegeneration and ageing. Ageing Res Rev. 2015;24(Pt B):138\u201359. https:\/\/doi.org\/10.1016\/j.arr.2015.07.009.","journal-title":"Ageing Res Rev."},{"key":"3008_CR17","doi-asserted-by":"publisher","first-page":"121643","DOI":"10.1016\/j.lfs.2023.121643","volume":"321","author":"V Akhouri","year":"2023","unstructured":"Akhouri V, Majumder S, Gaikwad AB. The emerging insight into E3 ligases as the potential therapeutic target for diabetic kidney disease. Life Sci. 2023;321:121643. https:\/\/doi.org\/10.1016\/j.lfs.2023.121643.","journal-title":"Life Sci."},{"issue":"45","key":"3008_CR18","doi-asserted-by":"publisher","first-page":"11944","DOI":"10.1073\/pnas.1715742114","volume":"114","author":"H Wang","year":"2017","unstructured":"Wang H, Meng H, Li X, Zhu K, Dong K, Mookhtiar AK, et al. PELI1 functions as a dual modulator of necroptosis and apoptosis by regulating ubiquitination of RIPK1 and mRNA levels of c-FLIP. Proc Natl Acad Sci USA. 2017;114(45):11944\u20139. https:\/\/doi.org\/10.1073\/pnas.1715742114.","journal-title":"Proc Natl Acad Sci USA."},{"issue":"10","key":"3008_CR19","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1038\/ni.2090","volume":"12","author":"M Chang","year":"2011","unstructured":"Chang M, Jin W, Chang JH, Xiao Y, Brittain GC, Yu J, et al. The ubiquitin ligase Peli1 negatively regulates T cell activation and prevents autoimmunity. Nat Immunol. 2011;12(10):1002\u20139. https:\/\/doi.org\/10.1038\/ni.2090.","journal-title":"Nat Immunol."},{"issue":"4","key":"3008_CR20","doi-asserted-by":"publisher","first-page":"109904","DOI":"10.1016\/j.celrep.2021.109904","volume":"37","author":"L Zhang","year":"2021","unstructured":"Zhang L, Ko CJ, Li Y, Jie Z, Zhu L, Zhou X, et al. Peli1 facilitates NLRP3 inflammasome activation by mediating ASC ubiquitination. Cell Rep. 2021;37(4):109904. https:\/\/doi.org\/10.1016\/j.celrep.2021.109904.","journal-title":"Cell Rep."},{"issue":"4","key":"3008_CR21","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1038\/s41423-021-00660-5","volume":"18","author":"X Huang","year":"2021","unstructured":"Huang X, Hao S, Liu J, Huang Y, Liu M, Xiao C, et al. The ubiquitin ligase Peli1 inhibits ICOS and thereby Tfh-mediated immunity. Cellul molecular immunol. 2021;18(4):969\u201378. https:\/\/doi.org\/10.1038\/s41423-021-00660-5.","journal-title":"Cellul molecular immunol."},{"issue":"1","key":"3008_CR22","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/s41389-023-00457-3","volume":"12","author":"J Qi","year":"2023","unstructured":"Qi J, Xu G, Wu X, Lu C, Shen Y, Zhao B. PELI1 and EGFR cooperate to promote breast cancer metastasis. Oncogenesis. 2023;12(1):9. https:\/\/doi.org\/10.1038\/s41389-023-00457-3.","journal-title":"Oncogenesis."},{"issue":"1","key":"3008_CR23","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s12967-021-03226-1","volume":"20","author":"T Zheng","year":"2022","unstructured":"Zheng T, Zhou Y, Xu X, Qi X, Liu J, Pu Y, et al. MiR-30c-5p loss-induced PELI1 accumulation regulates cell proliferation and migration via activating PI3K\/AKT pathway in papillary thyroid carcinoma. J Transl Med. 2022;20(1):20. https:\/\/doi.org\/10.1186\/s12967-021-03226-1.","journal-title":"J Transl Med."},{"issue":"6","key":"3008_CR24","doi-asserted-by":"publisher","first-page":"1384","DOI":"10.1002\/1878-0261.13134","volume":"16","author":"D Dai","year":"2022","unstructured":"Dai D, Zhou H, Yin L, Ye F, Yuan X, You T, et al. PELI1 promotes radiotherapy sensitivity by inhibiting noncanonical NF-\u03baB in esophageal squamous cancer. Mol Oncol. 2022;16(6):1384\u2013401. https:\/\/doi.org\/10.1002\/1878-0261.13134.","journal-title":"Mol Oncol."},{"issue":"49","key":"3008_CR25","doi-asserted-by":"publisher","first-page":"80350","DOI":"10.18632\/oncotarget.10180","volume":"7","author":"Y Kim","year":"2016","unstructured":"Kim Y, Lee MS, Kim HD, Kim J. Ribosomal protein S3 (rpS3) secreted from various cancer cells is N-linked glycosylated. Oncotarget. 2016;7(49):80350\u201362. https:\/\/doi.org\/10.18632\/oncotarget.10180.","journal-title":"Oncotarget."},{"issue":"9","key":"3008_CR26","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1038\/s41388-022-02581-7","volume":"42","author":"T Wang","year":"2023","unstructured":"Wang T, Jin C, Yang P, Chen Z, Ji J, Sun Q, et al. UBE2J1 inhibits colorectal cancer progression by promoting ubiquitination and degradation of RPS3. Oncogene. 2023;42(9):651\u201364.","journal-title":"Oncogene."},{"issue":"3","key":"3008_CR27","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1016\/j.bbrc.2011.09.099","volume":"414","author":"CY Jang","year":"2011","unstructured":"Jang CY, Shin HS, Kim HD, Kim JW, Choi SY, Kim J. Ribosomal protein S3 is stabilized by sumoylation. Biochem Biophys Res Commun. 2011;414(3):523\u20137. https:\/\/doi.org\/10.1016\/j.bbrc.2011.09.099.","journal-title":"Biochem Biophys Res Commun."},{"key":"3008_CR28","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.bbrc.2022.08.082","volume":"628","author":"A Imai","year":"2022","unstructured":"Imai A, Horinaka M, Aono Y, Iizumi Y, Takakura H, Ono H, et al. Salicylic acid directly binds to ribosomal protein S3 and suppresses CDK4 expression in colorectal cancer cells. Biochem Biophys Res Commun. 2022;628:110\u20135. https:\/\/doi.org\/10.1016\/j.bbrc.2022.08.082.","journal-title":"Biochem Biophys Res Commun."},{"issue":"1","key":"3008_CR29","doi-asserted-by":"publisher","first-page":"e434","DOI":"10.1038\/emm.2017.247","volume":"50","author":"W Kim","year":"2018","unstructured":"Kim W, Youn H, Lee S, Kim E, Kim D, Sub Lee J, et al. RNF138-mediated ubiquitination of rpS3 is required for resistance of glioblastoma cells to radiation-induced apoptosis. Exp Mol Med. 2018;50(1):e434. https:\/\/doi.org\/10.1038\/emm.2017.247.","journal-title":"Exp Mol Med."},{"issue":"8","key":"3008_CR30","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1038\/s41568-020-0262-1","volume":"20","author":"AJ Levine","year":"2020","unstructured":"Levine AJ. p53: 800 million years of evolution and 40 years of discovery. Nat Rev Cancer. 2020;20(8):471\u201380. https:\/\/doi.org\/10.1038\/s41568-020-0262-1.","journal-title":"Nat Rev Cancer."},{"issue":"1","key":"3008_CR31","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/s40880-019-0367-7","volume":"39","author":"ZQ Wang","year":"2019","unstructured":"Wang ZQ, Zhang F, Deng T, Zhang L, Feng F, Wang FH, et al. The efficacy and safety of modified FOLFIRINOX as first-line chemotherapy for Chinese patients with metastatic pancreatic cancer. Cancer commun (London England). 2019;39(1):26. https:\/\/doi.org\/10.1186\/s40880-019-0367-7.","journal-title":"Cancer commun (London England)."},{"issue":"1","key":"3008_CR32","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1182\/blood.2020009856","volume":"139","author":"Q Wang","year":"2022","unstructured":"Wang Q, Lin Z, Wang Z, Ye L, Xian M, Xiao L, et al. RAR\u03b3 activation sensitizes human myeloma cells to carfilzomib treatment through the OAS-RNase L innate immune pathway. Blood. 2022;139(1):59\u201372. https:\/\/doi.org\/10.1182\/blood.2020009856.","journal-title":"Blood."},{"issue":"Pt 2","key":"3008_CR33","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.semcancer.2020.03.007","volume":"67","author":"KM Nguyen","year":"2020","unstructured":"Nguyen KM, Busino L. Targeting the E3 ubiquitin ligases DCAF15 and cereblon for cancer therapy. Semin Cancer Biol. 2020;67(Pt 2):53\u201360. https:\/\/doi.org\/10.1016\/j.semcancer.2020.03.007.","journal-title":"Semin Cancer Biol."},{"issue":"10","key":"3008_CR34","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1038\/ni.2108","volume":"12","author":"PN Moynagh","year":"2011","unstructured":"Moynagh PN. Peli1 (rel)ieves autoimmunity. Nat Immunol. 2011;12(10):927\u20139.","journal-title":"Nat Immunol."},{"issue":"5","key":"3008_CR35","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1016\/j.molcel.2018.05.016","volume":"70","author":"SW Choi","year":"2018","unstructured":"Choi SW, Park HH, Kim S, Chung JM, Noh HJ, Kim SK, et al. PELI1 selectively targets kinase-active RIP3 for Ubiquitylation-dependent proteasomal degradation. Mol Cell. 2018;70(5):920\u201335.e7. https:\/\/doi.org\/10.1016\/j.molcel.2018.05.016.","journal-title":"Mol Cell."},{"issue":"2","key":"3008_CR36","doi-asserted-by":"publisher","first-page":"e104532","DOI":"10.15252\/embj.2020104532","volume":"40","author":"CJ Ko","year":"2021","unstructured":"Ko CJ, Zhang L, Jie Z, Zhu L, Zhou X, Xie X, et al. The E3 ubiquitin ligase Peli1 regulates the metabolic actions of mTORC1 to suppress antitumor T cell responses. EMBO J. 2021;40(2):e104532. https:\/\/doi.org\/10.15252\/embj.2020104532.","journal-title":"EMBO J."},{"issue":"12","key":"3008_CR37","doi-asserted-by":"publisher","first-page":"2943","DOI":"10.1016\/j.bbamcr.2013.07.015","volume":"1833","author":"Y Kim","year":"2013","unstructured":"Kim Y, Kim HD, Kim J. Cytoplasmic ribosomal protein S3 (rpS3) plays a pivotal role in mitochondrial DNA damage surveillance. Biochim Biophys Acta. 2013;1833(12):2943\u201352. https:\/\/doi.org\/10.1016\/j.bbamcr.2013.07.015.","journal-title":"Biochim Biophys Acta."},{"issue":"3","key":"3008_CR38","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/alzrt265","volume":"6","author":"Y Kitagishi","year":"2014","unstructured":"Kitagishi Y, Nakanishi A, Ogura Y, Matsuda S. Dietary regulation of PI3K\/AKT\/GSK-3\u03b2 pathway in Alzheimer's disease. Alzheimers Res Ther. 2014;6(3):35. https:\/\/doi.org\/10.1186\/alzrt265.","journal-title":"Alzheimers Res Ther."},{"issue":"3","key":"3008_CR39","doi-asserted-by":"publisher","first-page":"707","DOI":"10.20892\/j.issn.2095-3941.2020.0056","volume":"17","author":"Y Yuan","year":"2020","unstructured":"Yuan Y, Fan Y, Gao Z, Sun X, Zhang H, Wang Z, et al. SHP2 promotes proliferation of breast cancer cells through regulating cyclin D1 stability via the PI3K\/AKT\/GSK3\u03b2 signaling pathway. Cancer biol med. 2020;17(3):707\u201325. https:\/\/doi.org\/10.20892\/j.issn.2095-3941.2020.0056.","journal-title":"Cancer biol med."},{"issue":"1","key":"3008_CR40","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1038\/s41392-021-00828-5","volume":"6","author":"Y He","year":"2021","unstructured":"He Y, Sun MM, Zhang GG, Yang J, Chen KS, Xu WW, et al. Targeting PI3K\/Akt signal transduction for cancer therapy. Signal transduct target therapy. 2021;6(1):425. https:\/\/doi.org\/10.1038\/s41392-021-00828-5.","journal-title":"Signal transduct target therapy."},{"issue":"30","key":"3008_CR41","doi-asserted-by":"publisher","first-page":"4253","DOI":"10.1038\/onc.2010.189","volume":"29","author":"C Deisenroth","year":"2010","unstructured":"Deisenroth C, Zhang Y. Ribosome biogenesis surveillance: probing the ribosomal protein-Mdm2-p53 pathway. Oncogene. 2010;29(30):4253\u201360. https:\/\/doi.org\/10.1038\/onc.2010.189.","journal-title":"Oncogene."},{"issue":"1","key":"3008_CR42","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1038\/s41392-021-00728-8","volume":"6","author":"J Kang","year":"2021","unstructured":"Kang J, Brajanovski N, Chan KT, Xuan J, Pearson RB, Sanij E. Ribosomal proteins and human diseases: molecular mechanisms and targeted therapy. Signal transduct target therapy. 2021;6(1):323. https:\/\/doi.org\/10.1038\/s41392-021-00728-8.","journal-title":"Signal transduct target therapy."},{"issue":"1","key":"3008_CR43","doi-asserted-by":"publisher","first-page":"188662","DOI":"10.1016\/j.bbcan.2021.188662","volume":"1877","author":"A Ou","year":"2022","unstructured":"Ou A, Zhao X, Lu Z. The potential roles of p53 signaling reactivation in pancreatic cancer therapy. Biochimica et biophysica acta Rev cancer. 2022;1877(1):188662. https:\/\/doi.org\/10.1016\/j.bbcan.2021.188662.","journal-title":"Biochimica et biophysica acta Rev cancer."},{"issue":"4","key":"3008_CR44","doi-asserted-by":"publisher","first-page":"188914","DOI":"10.1016\/j.bbcan.2023.188914","volume":"1878","author":"J Calheiros","year":"2023","unstructured":"Calheiros J, Corbo V, Saraiva L. Overcoming therapeutic resistance in pancreatic cancer: emerging opportunities by targeting BRCAs and p53. Biochimica et biophysica acta Rev cancer. 2023;1878(4):188914. https:\/\/doi.org\/10.1016\/j.bbcan.2023.188914.","journal-title":"Biochimica et biophysica acta Rev cancer."}],"container-title":["Journal of Experimental &amp; Clinical Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-024-03008-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13046-024-03008-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-024-03008-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,25]],"date-time":"2024-03-25T08:05:34Z","timestamp":1711353934000},"score":1,"resource":{"primary":{"URL":"https:\/\/jeccr.biomedcentral.com\/articles\/10.1186\/s13046-024-03008-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,25]]},"references-count":44,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["3008"],"URL":"https:\/\/doi.org\/10.1186\/s13046-024-03008-9","relation":{},"ISSN":["1756-9966"],"issn-type":[{"value":"1756-9966","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,25]]},"assertion":[{"value":"22 November 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 March 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 March 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved and consented by the Human Ethics Committee of Guizhou Medical University Hospital and the Animal Ethics Committee of Guizhou Medical University. All subjects understood the purpose of the study and signed a written informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}},{"value":"All authors have consented to publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"91"}}